CANCOV is a consortium involving multiple studies across Canada. Our research ranges from genomics and epigenomics to antibody testing and immune analyses.

​We plan to recruit 2000 (1000 non-hospitalized and 1000 hospitalized) patients and 500 family caregivers from the four hardest-hit provinces in Canada: Quebec, Ontario, Alberta and British Columbia.

This project is built on the GEMINI in Ontario and the RECOVER network across Canada.

Our research will include 3 population cohorts of COVID-19:

NON-HOSPITALIZED PATIENTS

Patients who are diagnosed at COVID-19 assessment centres, emergency rooms and clinics, and told to isolate at home.

NON-ICU PATIENTS

Patients who are sick enough to require admission to acute care hospitals.

ICU PATIENTS

Patients who are critically ill and require admission to an intensive care unit (ICU) or mechanical ventilation.

We will get individual blood samples for genetic, transcriptomic and epigenomic samples. We will also obtain bank samples for serological, immune and cytokine profile testing at baseline.

Competent patients and caregivers will use an iPad to complete baseline demographic information including sociodemographic and clinical risk factors.

All patients will undergo a number of assessments at 1, 3, 6, and 12-months after admission to critical care hospitals. Tests include functional, neuropsychological, Health-Related Quality of Life (HRQoL), pattern and cost of healthcare utilization assessments.

The CANCOV program of research has 5 distinct projects:


HOST GENETIC PROFILING THROUGH WHOLE-GENOME SEQUENCING

DELINEATING TRANSCRIPTOMIC, EPIGENOMIC AND IMMUNOLOGIC HOST RESPONSE TO COVID-19 INFECTION

UNDERSTANDING HOW SOCIODEMOGRAPHIC AND CLINICAL FACTORS AFFECT SHORT-TERM OUTCOMES

EXPLAINING THE TRAJECTORIES OF RECOVERY FROM COVID-19 INFECTIONS AND THE DETERMINANTS OF LONG TERM OUTCOMES

EXPLAINING THE TRAJECTORIES OF RECOVERY FROM COVID-19 INFECTIONS AND THE DETERMINANTS OF LONG TERM OUTCOMES

COVID-19 Research

The CANCOV Program of Research will provide full description of the multi-organ morbidity of the COVID-19 infection. We will look across the spectrum of the illness and its impact on families.

The unique multi-omic evaluation of associated risk factors will bring new insights to instruments of COVID-19 related disease. They will help inform potential new targets for treatment.

CANCOV will raise the standard of care for patients with COVID-19. We will provide clinical pathways and guidelines, as well as open access prediction models and tools. As a result, this will help service providers and policymakers make better decisions.

CANCOV RESEARCH STUDIES

RECOVER PROGRAM

GEMINI HAL

COVIDEO

COVID-FREE@HOME

BEACONS

GENCOV

INTERFERON LAMBDA (INTERVENTIONAL TRIAL)

FRAILTY SUBCOHORT

CANADIAN STUDY OF YOUTH AND ADULTS WITH COVID-19: SHORT AND LONG-TERM IMPACT OF COMPLEMENT

PLASMA TRIAL FOLLOWUP

SUPPORT CANADA

VASCULAR ENDOTHELIUM FOR COVID19 PATHOGENESIS

HEALTH CARE WORKERS COHORT

PULMONARY FIBROSIS STUDY

COLOBILI/ ISARIC

ONTARIO NEURO-COVID

PODS

CGEN HOST SEQ